|Bid||0.0000 x 2200|
|Ask||0.0000 x 1200|
|Day's range||3.6900 - 3.7700|
|52-week range||2.9200 - 5.3500|
|Beta (3Y monthly)||0.73|
|PE ratio (TTM)||N/A|
|Earnings date||8 Jul 2019 - 18 Jul 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.50|
Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI): Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to addressRead More...
A look at the shareholders of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while Read More...
If you’re interested in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock Read More...
BrainStorm Cell Therapeutics Inc will not make its experimental stem cell treatment for neurodegenerative diseases available under the new U.S. "Right to Try" (RTT) act, citing a failure to find a way to enable all patients to afford the treatment. The U.S.-Israeli company said on Tuesday it will focus on completing its advanced study for NurOwn in patients with amyotrophic lateral sclerosis (ALS) as quickly as possible. U.S. Congress last month approved the RTT bill that would allow terminally ill patients to try experimental treatments not yet approved by the Food and Drug Administration.
A small biotechnology company may be the first to offer dying patients unproven drugs under a new U.S. law called Right to Try that deregulated access to such experimental treatments. While details are still being worked out, the company’s chief executive officer pointed to the price of bespoke cell therapies used to treat cancer that cost more than $300,000. “Companies cannot be NGOs,” the nongovernmental organizations that help provide care to impoverished countries, Brainstorm CEO Chaim Lebovits said in a phone interview.
Chaim Lebovits is the CEO of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), which has recently grown to a market capitalization of US$91.73M. Recognizing whether CEO incentives are aligned with shareholders isRead More...